Matinas BioPharma Holdings, Inc. (MTNB)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Matinas BioPharma Holdings, Inc. (MTNB) is up 10.9% since the beginning of the year. At $1 per share, MTNB is trading 79.0% below its 52-week high of $3. Investors who bought $1,000 worth of MTNB shares 5 years ago would now be looking at an investment worth $17.

Matinas BioPharma Holdings, Inc. (MTNB) has returned 10.94% so far this year and -26.13% over the past 12 months. Over the last ten years, MTNB has returned -32.45% per year, falling short of the S&P 500 Index benchmark, which averaged 13.71% annually.

Based on dividend-adjusted daily data since Aug 18, 2014, MTNB's average daily return is +0.16%, while the average monthly return is +1.62%. At this rate, an investment would double in approximately 3.6 years.

Historically, 44% of months were positive and 56% were negative. The best month was Aug 2025 with a return of +106.8%, while the worst month was Oct 2024 at -82.5%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 7 months.

On a daily basis, MTNB closed higher 43% of trading days. The best single day was Oct 11, 2023 with a return of +313.6%, while the worst single day was Oct 31, 2024 at -67.9%.

Matinas BioPharma Holdings, Inc. has an annualized alpha of 35.46%, beta of 0.87, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since August 18, 2014.

• This stock participated in 219.29% of S&P 500 Index downside but only 67.09% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

MTNB ranks 37 for risk / return — below 37% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Matinas BioPharma Holdings, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Matinas BioPharma Holdings, Inc. was 99.75%, occurring on Apr 8, 2026. The portfolio has not yet recovered.

The current Matinas BioPharma Holdings, Inc. drawdown is 99.66%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Matinas BioPharma Holdings, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Matinas BioPharma Holdings, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.